| Professional Services Industry | Industrials Sector | Mr. Katsuhito Hashizume CEO | XSAU Exchange | SA0007879642 ISIN |
| Japan Country | 58 Employees | 29 Jun 2026 Last Dividend | - Last Split | - IPO Date |
Human Metabolome Technologies, Inc. stands out as a biotechnology company with a keen focus on developing cutting-edge metabolomics technologies and solutions. Established in 2003 and operating out of Tsuruoka, Japan, this innovative company has carved a niche for itself in the realms of drug discovery, diagnosis, and food production. With a commitment to advancing scientific research and application, Human Metabolome Technologies fosters collaboration with prestigious institutions like the Institute for Advanced Biosciences and Keio University. This partnership aims to further the development of metabolome analysis technology, showcasing the company's dedication to pushing the boundaries of scientific exploration and application in metabolomics.
Human Metabolome Technologies, Inc. offers a comprehensive suite of metabolomics analysis services and solutions tailored to meet a wide range of scientific and industrial needs. Each service is designed with precision to provide valuable insights across various applications, ensuring clients achieve their research and development goals effectively.
In addition to these services, Human Metabolome Technologies tailors its approach to support various applications, including cancer metabolism, metabolic flux analysis, infectious diseases, basic science research, preclinical and clinical studies, food and nutrition, and microbiome research. Through this broad yet specialized service offering, the company addresses the diverse needs of its clientele, ultimately contributing to scientific advancement and innovation in biotechnology.